Quantcast

Latest Amines Stories

2013-12-03 23:32:27

Federal judge schedules key trial date from hundreds of cases from across the country.Resource4thePeople's national network of attorneys continues to provide free consultations to families with children allegedly suffering birth defects after use of SSRIs during pregnancies. San Diego, CA (PRWEB) December 03, 2013 http://www.resource4thepeople.com/defectivedrugs/SSRI-Birth-Defects.html Resource4thePeople announced today its latest update for consumers who have been following the...

2013-11-20 23:22:52

Modern Medical, a Healthcare Solutions company, today announced outcomes for its Opioid Defense Manager™ (ODM) program. Launched in November 2012, ODM is Modern Medical’s managed care program to stop the rising opioid abuse in the workers’ compensation industry by reducing inappropriate drug use and still maintaining the necessary balance to provide pain relief for the claimant. Columbus, OH (PRWEB) November 20, 2013 Modern Medical, a Healthcare Solutions company, today announced...

2013-11-19 13:21:53

Reports new study in Biological Psychiatry Two years ago, mammalian target of rapamycin or mTOR, a signaling protein, was identified as a key mediator of the antidepressant effects of ketamine, the first rapidly acting antidepressant medication to be identified. Several years later, a group at the National Institutes of Mental Health Intramural Program reported that scopolamine, a muscarinic acetylcholine receptor antagonist, also produced rapidly appearing antidepressant effects,...

2013-11-12 23:20:13

Countervail’s advanced development contract with BARDA fully realized is valued at $24.9 million over a five year period. Sarin, Soman, VX, Tabun, and Cyclosarin are examples of extremely toxic organophosphorus based compounds created for use as chemical weapons. Charlotte, NC (PRWEB) November 12, 2013 CHARLOTTE, NC, Nov 8, 2013 /PRWeb/ -- Countervail Corporation announced today the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development...

2013-11-04 23:19:01

Reportbuyer.com just published a new market research report: PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022. London (PRWEB) November 04, 2013 PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch...

2013-11-04 23:04:31

Reportbuyer.com just published a new market research report: PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022. London (PRWEB) November 04, 2013 PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'